Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Status:
Terminated
Trial end date:
2013-07-17
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving fludarabine and cyclophosphamide together
with total-body irradiation and rituximab works in treating patients with B-cell lymphoma or
chronic lymphocytic leukemia who are undergoing an allogeneic (donor) bone marrow transplant.
The type of bone marrow transplant is a less intensive or "mini" transplant using a relative
as the bone marrow donor. The donated bone marrow stem cells may replace the patient's immune
system cells and help destroy any remaining cancer (graft-versus-tumor effect). Patients
undergoing this type of transplant often have more than one relative who could be a donor.
The trial is also studying a new way of choosing amongst possible donors which might improve
how the rituximab works.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins